# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimat...
RBC Capital analyst Luca Issi maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price targe...
Barclays analyst Gena Wang initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight rating and announ...
BMO Capital analyst Kostas Biliouris maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and lowers the pric...
Jefferies analyst Nalin Tejavibulya maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target...
4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine...
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EM...